December 22, 2025 Quanterix Announces Landmark Nature Study Redefining Alzheimer’s Disease Neuropathology Prevalence read more
November 20, 2025 Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth read more
November 17, 2025 Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring read more
CTAD 2024 Quanterix Fireside Chat with Henrik Zetterburg: Advances in Blood-Based Biomarkers for Alzheimer’s Disease read more
October 9, 2025 Built for Translation: Why Simoa Stands Alone in Clinical-Grade Biomarker Measurement read more